Context Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Martin Lehr (38 yo)

7.67yrs

Tenure

US$1,587,791

Compensation

Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. He was a...


CEO Compensation Analysis

Martin Lehr's Compensation vs Context Therapeutics Earnings
How has Martin Lehr's remuneration changed compared to Context Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$2mUS$291k

-US$10m

Sep 30 2021n/an/a

-US$2m

Jun 30 2021n/an/a

-US$7m

Mar 31 2021n/an/a

-US$648k

Dec 31 2020US$250kUS$250k

US$1m

Dec 31 2019US$250kUS$250k

-US$6m

Compensation vs Market: Martin's total compensation ($USD1.59M) is above average for companies of similar size in the US market ($USD772.00K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CNTX's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

Experienced Board: CNTX's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.